Literature DB >> 9353074

Lethal tuberculosis in interleukin-6-deficient mutant mice.

C H Ladel1, C Blum, A Dreher, K Reifenberg, M Kopf, S H Kaufmann.   

Abstract

Tuberculosis is a chronic infectious disease which causes major health problems globally. Acquired resistance is mediated by T lymphocytes and executed by activated macrophages. In vitro studies have emphasized the importance of macrophage activation for mycobacterial growth inhibition. In vivo, the protective host response is focused on granulomatous lesions in which Mycobacterium tuberculosis is contained. A cellular immune response of the T helper 1 (Th1) type is considered central for control of tuberculosis. Using interleukin-6 (IL-6)-deficient mice, we here demonstrate a crucial role of this pluripotent cytokine in protection against M. tuberculosis but not against Mycobacterium bovis BCG. Infection with M. tuberculosis was lethal for the IL-6-deficient mice at inocula that were still controlled by IL-6-competent mice. Spleen cells from M. tuberculosis-infected IL-6-/- mouse mutants produced elevated levels of IL-4 and reduced levels of gamma interferon compared to the control levels. Cytofluorometric analyses of spleen cells from M. tuberculosis-infected mice revealed more-profound alterations in T-cell ratios in IL-6-/- mice than in control mice. We assume that IL-6 contributes to host resistance by its proinflammatory activity and by its influence on cytokine secretion.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9353074      PMCID: PMC175695          DOI: 10.1128/iai.65.11.4843-4849.1997

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  53 in total

1.  Effects of in vivo T lymphocyte subset depletion on mycobacterial infections in mice.

Authors:  C M Flory; R D Hubbard; F M Collins
Journal:  J Leukoc Biol       Date:  1992-03       Impact factor: 4.962

Review 2.  Interleukin-6 and its receptor: a paradigm for cytokines.

Authors:  T Kishimoto; S Akira; T Taga
Journal:  Science       Date:  1992-10-23       Impact factor: 47.728

3.  Stimulation of antibacterial macrophage activities by B-cell stimulatory factor 2 (interleukin-6).

Authors:  I E Flesch; S H Kaufmann
Journal:  Infect Immun       Date:  1990-01       Impact factor: 3.441

Review 4.  Interleukin-6: an overview.

Authors:  J Van Snick
Journal:  Annu Rev Immunol       Date:  1990       Impact factor: 28.527

Review 5.  Immunity to intracellular bacteria.

Authors:  S H Kaufmann
Journal:  Annu Rev Immunol       Date:  1993       Impact factor: 28.527

6.  Protective effect of anti-interleukin (IL)-6 antibody against endotoxin, associated with paradoxically increased IL-6 levels.

Authors:  H Heremans; C Dillen; W Put; J Van Damme; A Billiau
Journal:  Eur J Immunol       Date:  1992-09       Impact factor: 5.532

Review 7.  IL-6 and NF-IL6 in acute-phase response and viral infection.

Authors:  S Akira; T Kishimoto
Journal:  Immunol Rev       Date:  1992-06       Impact factor: 12.988

8.  Multiple defects of immune cell function in mice with disrupted interferon-gamma genes.

Authors:  D K Dalton; S Pitts-Meek; S Keshav; I S Figari; A Bradley; T A Stewart
Journal:  Science       Date:  1993-03-19       Impact factor: 47.728

9.  Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection.

Authors:  J L Flynn; M M Goldstein; K J Triebold; B Koller; B R Bloom
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

Review 10.  Tuberculosis: commentary on a reemergent killer.

Authors:  B R Bloom; C J Murray
Journal:  Science       Date:  1992-08-21       Impact factor: 47.728

View more
  133 in total

1.  Effects of exogenous interleukin-6 during Pseudomonas aeruginosa corneal infection.

Authors:  N Cole; M Krockenberger; S Bao; K W Beagley; A J Husband; M Willcox
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

Review 2.  Averting inflammation by targeting the cytokine environment.

Authors:  Manfred Kopf; Martin F Bachmann; Benjamin J Marsland
Journal:  Nat Rev Drug Discov       Date:  2010-09       Impact factor: 84.694

3.  A role for tumour necrosis factor-alpha, complement C5 and interleukin-6 in the initiation and development of the mycobacterial cord factor trehalose 6,6'-dimycolate induced granulomatous response.

Authors:  Kerry J Welsh; April N Abbott; Shen-An Hwang; Jessica Indrigo; Lisa Y Armitige; Michael R Blackburn; Robert L Hunter; Jeffrey K Actor
Journal:  Microbiology (Reading)       Date:  2008-06       Impact factor: 2.777

4.  Protection of mice from Mycobacterium tuberculosis by ID87/GLA-SE, a novel tuberculosis subunit vaccine candidate.

Authors:  Hillarie Plessner Windish; Malcolm S Duthie; Ayesha Misquith; Greg Ireton; Elyse Lucas; John D Laurance; Remy H Bailor; Rhea N Coler; Steven G Reed
Journal:  Vaccine       Date:  2011-08-02       Impact factor: 3.641

5.  Dose-dependent induction of IL-6 by plant-derived proteases in vitro.

Authors:  B Rose; C Herder; H Löffler; G Meierhoff; N C Schloot; M Walz; S Martin
Journal:  Clin Exp Immunol       Date:  2006-01       Impact factor: 4.330

6.  Serum concentrations of cytokines in patients with active tuberculosis (TB) and after treatment.

Authors:  A Verbon; N Juffermans; S J Van Deventer; P Speelman; H Van Deutekom; T Van Der Poll
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

7.  TLR9 regulates the mycobacteria-elicited pulmonary granulomatous immune response in mice through DC-derived Notch ligand delta-like 4.

Authors:  Toshihiro Ito; Matthew Schaller; Cory M Hogaboam; Theodore J Standiford; Matyas Sandor; Nicholas W Lukacs; Stephen W Chensue; Steven L Kunkel
Journal:  J Clin Invest       Date:  2008-12-15       Impact factor: 14.808

8.  Interleukin-6 deficiency influences cytokine expression in susceptible BALB mice infected with Leishmania major but does not alter the outcome of disease.

Authors:  R G Titus; G K DeKrey; R V Morris; M B Soares
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

9.  IL-6-dependent mucosal protection prevents establishment of a microbial niche for attaching/effacing lesion-forming enteric bacterial pathogens.

Authors:  Sara M Dann; Martina E Spehlmann; Dustin C Hammond; Mitsutoshi Iimura; Koji Hase; Lillian J Choi; Elaine Hanson; Lars Eckmann
Journal:  J Immunol       Date:  2008-05-15       Impact factor: 5.422

10.  Cutting edge: IL-6 is a marker of inflammation with no direct role in inflammasome-mediated mouse models.

Authors:  Matthew D McGeough; Carla A Pena; James L Mueller; Derek A Pociask; Lori Broderick; Hal M Hoffman; Susannah D Brydges
Journal:  J Immunol       Date:  2012-08-17       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.